Sergio Masián Barroso

Idoven is a health technology company advancing early detection and precision medicine for cardiovascular diseases. The Idoven AI-powered platform delivers substantial improvements to the speed, consistency and accuracy of electrocardiogram (ECG) interpretation. Its powerful, proprietary AI algorithms, which work with existing ECG devices, are also being applied to develop disease biomarkers towards patient identification, risk stratification and prognosis, as well as drug cardiac safety monitoring. Idoven partners with leading medical device and pharmaceutical companies on AI-driven innovations to develop a new standard of cardiovascular care. Through exclusive partnerships and research collaborations, Idoven has developed one of the world’s largest ECG databases and a deep learning system applied to cardiology. The Idoven software is designed to be integrated seamlessly into existing clinical and research workflows, to support clinician decision making and disease management. Idoven has been awarded with numerous distinctions for its AI technology in Europe and the US, including the prestigious European Innovation Council (EIC) Accelerator and Horizon 2020 (H2020) awards and the Healthy Longevity Catalyst Award from the US National Academy of Medicine. The company is backed by top tier investors including Insight Partners, Northzone and Wayra (Telefónica), the Accel Starters programme, leading business angels and EIT Health. Idoven is based in Madrid and was founded in 2018, following almost a decade of ground-breaking research. We are building the future of cardiovascular care, and we need the best minds from around the world to help us. Interested in joining our team? Head to our careers page and apply at www.idoven.ai/jobs

CESIF es una institución privada, nacida en 1990, cuya actividad está centrada en formación y consultoría específicas para las industrias farmacéutica, parafarmacéutica, biotecnológica, alimentaria, química, cosmética y -en general- en todos aquellos sectores afines a la sanidad.

Idoven is a health technology company advancing early detection and precision medicine for cardiovascular diseases. The Idoven AI-powered platform delivers substantial improvements to the speed, consistency and accuracy of electrocardiogram (ECG) interpretation. Its powerful, proprietary AI algorithms, which work with existing ECG devices, are also being applied to develop disease biomarkers towards patient identification, risk stratification and prognosis, as well as drug cardiac safety monitoring. Idoven partners with leading medical device and pharmaceutical companies on AI-driven innovations to develop a new standard of cardiovascular care. Through exclusive partnerships and research collaborations, Idoven has developed one of the world’s largest ECG databases and a deep learning system applied to cardiology. The Idoven software is designed to be integrated seamlessly into existing clinical and research workflows, to support clinician decision making and disease management. Idoven has been awarded with numerous distinctions for its AI technology in Europe and the US, including the prestigious European Innovation Council (EIC) Accelerator and Horizon 2020 (H2020) awards and the Healthy Longevity Catalyst Award from the US National Academy of Medicine. The company is backed by top tier investors including Insight Partners, Northzone and Wayra (Telefónica), the Accel Starters programme, leading business angels and EIT Health. Idoven is based in Madrid and was founded in 2018, following almost a decade of ground-breaking research. We are building the future of cardiovascular care, and we need the best minds from around the world to help us. Interested in joining our team? Head to our careers page and apply at www.idoven.ai/jobs

SILO is a strategy consultancy firm -with offices in Madrid, Galicia and Basque Country- working on innovation policy and business development for the high tech sector. Our team has extensive public-private expertise in the design, implementation and evaluation of tailored solutions for a wide variety of innovation agents. Our background in healthcare and biotechnology makes SILO a unique choice for hospitals, public institutions and pharma/medtech companies looking for strategic and operational advantage